258 related articles for article (PubMed ID: 19293256)
1. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.
Singh S; Sadanandam A; Nannuru KC; Varney ML; Mayer-Ezell R; Bond R; Singh RK
Clin Cancer Res; 2009 Apr; 15(7):2380-6. PubMed ID: 19293256
[TBL] [Abstract][Full Text] [Related]
2. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Shang FM; Li J
Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
[TBL] [Abstract][Full Text] [Related]
3. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.
Varney ML; Singh S; Li A; Mayer-Ezell R; Bond R; Singh RK
Cancer Lett; 2011 Jan; 300(2):180-8. PubMed ID: 21035946
[TBL] [Abstract][Full Text] [Related]
4. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
[TBL] [Abstract][Full Text] [Related]
5. Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.
Singh S; Sadanandam A; Varney ML; Nannuru KC; Singh RK
Int J Cancer; 2010 Jan; 126(2):328-36. PubMed ID: 19585580
[TBL] [Abstract][Full Text] [Related]
6. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Kemp DM; Pidich A; Larijani M; Jonas R; Lash E; Sato T; Terai M; De Pizzol M; Allegretti M; Igoucheva O; Alexeev V
Oncotarget; 2017 Feb; 8(9):14428-14442. PubMed ID: 28129639
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
8. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
10. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
11. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
[TBL] [Abstract][Full Text] [Related]
12. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.
Singh S; Nannuru KC; Sadanandam A; Varney ML; Singh RK
Br J Cancer; 2009 May; 100(10):1638-46. PubMed ID: 19401689
[TBL] [Abstract][Full Text] [Related]
13. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA
J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
[TBL] [Abstract][Full Text] [Related]
14. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
15. Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer.
Prajapati DR; Molczyk C; Purohit A; Saxena S; Sturgeon R; Dave BJ; Kumar S; Batra SK; Singh RK
Cancer Lett; 2023 Jun; 563():216185. PubMed ID: 37062329
[TBL] [Abstract][Full Text] [Related]
16. Herbacetin suppressed MMP9 mediated angiogenesis of malignant melanoma through blocking EGFR-ERK/AKT signaling pathway.
Li L; Fan P; Chou H; Li J; Wang K; Li H
Biochimie; 2019 Jul; 162():198-207. PubMed ID: 31075281
[TBL] [Abstract][Full Text] [Related]
17. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
[TBL] [Abstract][Full Text] [Related]
19. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.
Sharma B; Singh S; Varney ML; Singh RK
Expert Opin Ther Targets; 2010 Apr; 14(4):435-42. PubMed ID: 20230195
[TBL] [Abstract][Full Text] [Related]
20. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
